3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations

Villarreal-Barragan brings global experience delivering first-in-human and complex biomarker-driven oncology trials for Gilead Sciences, Kite Pharma, and emerging biotech companies SOUTH SAN FRANCISCO, Calif., – March 2, 2026 – 3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms. Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-